文献速递艾滋病与性传播感染

HIV-1感染者抗逆转录病毒治疗中断的系统综述与荟萃分析:对未来治愈试验的启示

Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1-infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该系统综述与荟萃分析纳入22项研究共7104例HIV-1感染者,分析分析性治疗中断(ATI)期间不良事件(AE)的发生情况。结果显示,中断>4周时AE总比例为3%(95%CI 0%-7%),随访间隔≤14天的研究AE比例(0%,95%CI 0%-1%)低于随访间隔更宽的研究(6%,95%CI 2%-13%;结论认为,在密切监测HIV-1反弹的前提下,ATI可能是HIV-1治愈试验中的安全策略。

要点

  • ATI期间AE总比例低,中断>4周时为3%(95%CI 0%-7%)。
  • 随访间隔≤14天的研究AE比例更低(0%,95%CI 0%-1%)。
  • ATI作为HIV-1治愈试验策略需密切监测病毒反弹。

核心结论

  • 中等质量证据表明,随访间隔较窄的研究中ATI期间AE未见显著增加。
  • 在密切监测HIV-1反弹的前提下,ATI可能是HIV-1治愈试验中的安全策略。

研究设计与样本

  • 系统综述与荟萃分析,纳入干预性和观察性研究。
  • 检索到1048项研究,最终纳入22项研究共7104例HIV-1感染者。
  • 纳入研究样本量6至5472例,TI周期时长7天至27个月。

主要发现

  • ATI期间HIV-1-RNA检测间隔从2天至3个月不等。
  • 中断>4周时AE总比例为3%(95%CI 0%-7%)。

临床怎么用

  • ATI用于HIV-1治愈试验时应密切监测HIV-1反弹。
  • 采用较窄的随访间隔(如≤14天)可能降低AE风险。

局限性

  • 纳入研究间随访间隔和TI周期时长差异较大。
  • 证据质量为中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safety and tolerability of analytical treatment interruptions (ATIs) as a vital part of human immunodeficiency virus type 1 (HIV-1) cure studies are discussed. We analyzed current evidence for the occurrence of adverse events (AEs) during TIs. METHODS: Our analysis included studies that reported on AEs in HIV-1-infected patients undergoing TIs. All interventional and observational studies were reviewed, and results were extracted based on predefined criteria. The proportion of AEs was pooled using random-effects models. Metaregression was used to explore the influence of baseline CD4+ T-cell count, viral load, study type, previous time on combined antiretroviral therapy, and follow-up interval during TIs. RESULTS: We identified 1048 studies, of which 22 studies including 7104 individuals fulfilled the defined selection criteria. Included studies had sample sizes between 6 and 5472 participants, with durations of TI cycles ranging from 7 days to 27 months. The intervals of HIV-1-RNA testing varied from 2 days to 3 months during TIs. The overall proportion of AEs during TIs >4 weeks was 3% (95% confidence interval [CI], 0%-7%) and was lower in studies with follow-up intervals ≤14 days (0%; 95% CI, 0%-1%) than in studies with wider follow-up intervals (6%; 95% CI, 2%-13%; P value for interaction = .01). CONCLUSIONS: We found moderate-quality evidence indicating that studies with narrow follow-up intervals did not show a substantial increase in AEs during TIs. Our findings indicate that ATI may be a safe strategy as part of HIV-1 cure trials by closely monitoring for HIV-1 rebound.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Stecher M, Claßen A, Klein F, et al. Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1-infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials. Clin Infect Dis. 2020. PMID: 31102444. doi:10.1093/cid/ciz417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。